We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarker Protein Investigated in Juvenile Idiopathic Arthritis

By LabMedica International staff writers
Posted on 09 Mar 2021
Print article
Image: An enzyme-linked immunosorbent assay (ELISA) measured serum 14–3-3η levels and evaluated in juvenile idiopathic arthritis (Photo courtesy of Quest Diagnostics).
Image: An enzyme-linked immunosorbent assay (ELISA) measured serum 14–3-3η levels and evaluated in juvenile idiopathic arthritis (Photo courtesy of Quest Diagnostics).
Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatologic disease that may persist into adulthood and impact quality of life. The diagnosis is mainly based on clinical assessment rather than relying on laboratory testing.

The disease course and prognosis of JIA may vary based on multiple factors such as presence of the biomarkers rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibodies. RF-seropositive polyarticular JIA (PJIA RF+) has similar features as adult rheumatoid arthritis (RA) and may extend into adulthood. The biomarker 14–3-3η is highly sensitive and specific for RA in adults.

Rheumatologists and their colleagues at the Children's Hospital of Los Angeles (Los Angeles, CA, USA) recruited 151 JIA patients who were categorized into five groups: polyarticular JIA RF+ (PJIA RF+; n = 39), PJIA RF- (n = 39), psoriatic arthritis (PsA; n = 19), enthesitis-related arthritis (ERA; n = 18), and oligoarticular JIA (OJIA [control group]; n = 36). Laboratory studies, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), were obtained at the same time.

Specimens for CCP antibody, RF, antinuclear antibody (ANA), and HLA-B27 testing were also obtained. Samples for 14–3-3η were centrifuged and the serum was collected. Serum was stored in a freezer and sent to Quest Diagnostics Nichols Institute (San Juan Capistrano, CA, USA) overnight. 14–3-3η was measured via enzyme-linked immunosorbent assay (ELISA) at Quest Diagnostics. A 14–3-3η serum level of > 0.2 ng/mL was considered positive.

The team reported that elevated 14-3-3η levels were detected in 34/151 (23%) patients, and across all groups tested. Most patients with 14-3-3η had titers ≥4 times above the cutoff value. The majority (22, 65%) of 14-3-3η-positive patients were also positive for RF or CCP antibodies, 16 (47%) were positive for all three, and 12 (35%) were single-positive for 14-3-3η. The highest prevalence of 14-3-3η was in PJIA RF+ patients (49%), followed by OJIA (22%). Positivity for 14-3-3η was not significantly associated with disease activity or age at diagnosis.

The authors concluded that serum 14-3-3η can be detected in all forms of JIA tested, but appears to be most common in PJIA RF+. However, 14-3-3η does not appear to correlate with disease activity in JIA. The study was published on February 16, 2021 in the journal Pediatric Rheumatology.

Related Links:
Children's Hospital of Los Angeles
Quest Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.